About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Proactive Chlamydia Screening Is Not Good Value for Money

by VR Sreeraman on July 29, 2007 at 3:41 PM
Font : A-A+

Proactive Chlamydia Screening Is Not Good Value for Money

Proactive chlamydia screening for young adults is an expensive intervention that probably does not represent good value for money, concludes a study.

There are two types of screening - proactive and opportunistic. Proactive screening uses population registers to invite people to be screened regularly, while opportunistic screening targets people attending health services for unrelated reasons.

Advertisement

In England, chlamydia screening is mainly opportunistic, but in some areas general practices registers are being used to send proactive invitations to potentially eligible people to remind them to be re-screened.

Most studies have suggested that chlamydia screening is cost-effective, but there are now questions surrounding the validity of these results. So researchers set out to compare the cost effectiveness of proactive screening with a policy of no organised screening.
Advertisement

Using a mathematical model, screening was offered proactively to a hypothetical population of 50,000 men and women aged 16-24 years. A dynamic model was used to give the closest possible approximation to the real sexual behaviour of this population.

Previous studies have used static models that are inappropriate for evaluating an infectious disease.

The cost-effectiveness of screening was based on major outcomes averted, defined as pelvic inflammatory disease, ectopic pregnancy, infertility, or neonatal complications.

For screening men and women, the incremental cost effectiveness ratio per major outcome averted after eight years was approximately £28,900 compared with no organised screening. It was less costly to screen women only but also less effective, and the incremental cost effectiveness ratio per major outcome averted was approximately £22,300.

Pelvic inflammatory disease was the most frequently avoided outcome.

When the incidence of major complications and uptake of screening were increased (but to values unlikely to be seen in real life), the cost effectiveness ratio fell to £6,200 per major outcome averted for screening women only.

The authors conclude: "Our evaluation of proactive population chlamydia screening, using a dynamic model incorporating realistic estimates of partner notification, the uptake of screening, and the incidence of severe complications, has shown it to be an expensive intervention that probably does not represent good value for money."

Source: Newswise
SRM
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chlamydia Trachomatis Vaginosis Chlamydia Test 

Recommended Reading
Chlamydia Trachomatis
Chlamydia is a sexually transmitted disease affecting mainly the genito-urinary system....
Chlamydia Test
Screening for chlamydial infection is recommended in women at high-risk for developing the ......
Vaginosis
Bacterial vaginosis (BV) is a disorder characterized by an offensive vaginal discharge & it is most ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use